Drug Safety

, Volume 31, Issue 10, pp 823–837 | Cite as

Drug-Induced Pancreatitis

Incidence, Management and Prevention
Review Article

Abstract

Drugs are a relatively rare cause of acute pancreatitis, with an estimated incidence of 0.1-2%. Many drugs have been suspected of causing pancreatitis, but the true incidence is not known as the evidence is derived mainly from random case reports. Case reports with the strongest evidence are those that clearly diagnose pancreatitis and exclude common aetiologies, provide the dose and time interval between the start of treatment with the suspected drug and the development of pancreatitis, document response to withdrawal of the drug, and demonstrate recurrent pancreatitis upon rechallenge with the drug. Few data exist on the mechanisms of drug-induced pancreatitis. Certain subpopulations such as children, women, the elderly and patients with advanced HIV infection or inflammatory bowel disease may be at higher risk. The diagnosis of drug-induced pancreatitis is often challenging because there are no unique clinical characteristics to distinguish drugs from other causes of pancreatitis. The majority of cases are mild, but severe and even fatal cases may occur, thus making identification of the offending agent critical. Management of drug-induced acute pancreatitis requires withdrawal of the offending agent and supportive care. Prevention of drug-induced pancreatitis requires an up-to-date knowledge of drugs that have the strongest evidence linking their use to the development of pancreatitis as well as the proposed mechanisms through which they may cause the reaction. In this paper, the epidemiology, diagnosis, management and prevention of drug-induced pancreatitis is reviewed. Drugs and classes of drugs strongly implicated as causing acute pancreatitis, based on well documented case reports, are discussed in detail.

Keywords

Pancreatitis Acute Pancreatitis Valproic Acid Lisinopril Visceral Leishmaniasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Banks PA, Freeman ML. Practice guidelines in acute pancrea-titis. Am J Gastroenterol 2006; 101: 2379–400PubMedCrossRefGoogle Scholar
  2. 2.
    Pandol SJ, Saluja AK, Imrie CW. Acute pancreatitis: bench to the bedside. Gastroenterology 2007; 132: 1127–51PubMedCrossRefGoogle Scholar
  3. 3.
    Johnston DH, Cornish A. Acute pancreatitis in patients receiving chlorothiazide. JAMA 1959; 170: 2054–6CrossRefGoogle Scholar
  4. 4.
    Zion MM, Goldberg B, Suzman MM. Corticotrophin and cortisone in the treatment of scleroderma [letter]. Q J Med 1955; 24: 215PubMedGoogle Scholar
  5. 5.
    Lancashire RJ, Cheng K, Langman MJ. Discrepancies between population-based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis. Aliment Pharmacol Ther 2003; 17: 887–93PubMedCrossRefGoogle Scholar
  6. 6.
    Mallory A, Kern F. Drug induced pancreatitis: a critical review. Gastroenterology 1980; 78: 813–20PubMedGoogle Scholar
  7. 7.
    Underwood TW, Frye CB. Drug-induced pancreatitis. Clin Pharm 1993; 12: 440–8PubMedGoogle Scholar
  8. 8.
    McArthur KE. Drug-induced pancreatitis. Aliment Pharmacol Ther 1996; 10: 23–38PubMedCrossRefGoogle Scholar
  9. 9.
    Wilmink T, Frick TW. Drug-induced pancreatitis. Drug Saf 1996; 14: 406–23PubMedCrossRefGoogle Scholar
  10. 10.
    Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an update. J Clin Gastroenterol 2005; 39: 709–16PubMedCrossRefGoogle Scholar
  11. 11.
    Badalov N, Baradarian R, Iswara K, et al. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol 2007; 5: 648–61PubMedCrossRefGoogle Scholar
  12. 12.
    Dhir R, Brown DK, Olden KW. Drug-induced pancreatitis: a practical review. Drugs Today 2007; 43: 499–07PubMedCrossRefGoogle Scholar
  13. 13.
    Maringhini A, Termini A, Patti R, et al. Enalapril-associated pancreatitis: recurrence after rechallenge. Am J Gastroenterol 1997; 92: 166–7PubMedGoogle Scholar
  14. 14.
    Carnovale A, Esposito P, Bassano P, et al. Enalapril-induced acute recurrent pancreatitis. Dig Liver Dis 2003; 35: 55–7PubMedCrossRefGoogle Scholar
  15. 15.
    Gershon T, Olshaker JS. Acute pancreatitis following lisinopril rechallenge. Am J Emerg Med 1998; 16: 523–4PubMedCrossRefGoogle Scholar
  16. 16.
    Kanbay M, Selcuk H, Yilmaz U. Recurrent acute pancreatitis secondary to lisinopril. South Med J 2006; 99: 1388–9PubMedCrossRefGoogle Scholar
  17. 17.
    Kanbay M, Korkmaz M, Yilmaz U, et al. Acute pancreatitis due to ramipril therapy. Postgrad Med J 2004; 80: 617–8PubMedCrossRefGoogle Scholar
  18. 18.
    Bosch X. Losartan-induced acute pancreatitis. Ann Intern Med 1997; 127: 1043–4PubMedGoogle Scholar
  19. 19.
    Birck R, Keim V, Fiedler F, et al. Pancreatitis after losartan [letter]. Lancet 1998; 351: 1178PubMedCrossRefGoogle Scholar
  20. 20.
    Van der Heide H, Ten Haaft MA, Stricker BH. Pancreatitis caused by methyldopa. BMJ (Clin Res Ed) 1981; 282: 1930–1CrossRefGoogle Scholar
  21. 21.
    Rominger JM. Gutierrez JG. Curtis D, et al. Methyldopa-in-duced pancreatitis. Am J Dig Dis 1978; 23: 756–8PubMedCrossRefGoogle Scholar
  22. 22.
    Jones PE. Oelbaum MH. Furosemide induced pancreatitis. BMJ 1975; 1: 133–4Google Scholar
  23. 23.
    Juang P, Page RL, Zolty R. Probable loop diuretic-induced pancreatitis in a sulfonamide-allergic patient. Ann Pharmacother 2006; 40: 128–34PubMedCrossRefGoogle Scholar
  24. 24.
    Cornish AL, McClellan JT, Johnston DH. Effects of chlorothiazide on the pancreas. N Engl J Med 1961; 265: 673–5PubMedCrossRefGoogle Scholar
  25. 25.
    Rion RJ. Recurrent pancreatitis after treatment with hydrochlorothiazide. J Am Board Fam Pract 1994; 7: 74–6PubMedGoogle Scholar
  26. 26.
    Bosch X, Bernadich O. Acute pancreatitis during treatment with amiodarone [letter]. Lancet 1997; 350: 1300PubMedCrossRefGoogle Scholar
  27. 27.
    Ceciliato R, Pezzilli R, Corinaldesi R, et al. Acute pancreatitis due to simvastatin therapy: increased severity after rechallenge. Dig Liver Dis 2004; 36: 639–40PubMedCrossRefGoogle Scholar
  28. 28.
    Johnson JL, Loomis IB. A case of simvastatin-associated pancreatitis and review of statin-associated pancreatitis. Pharmacotherapy 2006; 26: 414–22PubMedCrossRefGoogle Scholar
  29. 29.
    Anagnostopoulos GK, Tsiakos S, Margantinis G, et al. Acute pancreatitis due to pravastatin therapy. JOP 2003; 4: 129–32PubMedGoogle Scholar
  30. 30.
    Tysk C, Al-Eryani AY, Shawabkeh AA. Acute pancreatitis induced by fluvastatin therapy. J Clin Gastroenterol 2002; 35: 406–8PubMedCrossRefGoogle Scholar
  31. 31.
    Gang N, Langevitz P, Livneh A. Relapsing acute pancreatitis induced by re-exposure to the cholesterol lowering agent bezafibrate. Am J Gastroenterol 1999; 94: 3626–8PubMedCrossRefGoogle Scholar
  32. 32.
    Elmore MF, Rogge JD. Tetracycline-induced pancreatitis. Gastroenterology 1981; 81: 1134–6PubMedGoogle Scholar
  33. 33.
    Torosis J, Vender R. Tetracycline-induced acute pancreatitis. J Clin Gastroenterol 1987; 9: 580–1PubMedCrossRefGoogle Scholar
  34. 34.
    Sanford KA, Mayle JE, Dean HA, et al. Metronidazole-associated pancreatitis. Ann Intern Med 1988; 109: 756–7PubMedGoogle Scholar
  35. 35.
    Celifarco A, Warschauer C, Burakoff R. Metronidazole induced pancreatitis. Am J Gastroenterol 1989; 84: 958–63PubMedGoogle Scholar
  36. 36.
    Jha SH, Reddy JA, Dave JK. Dapsone-induced acute pancreatitis. Ann Pharmacother 2003; 37: 1438–40PubMedCrossRefGoogle Scholar
  37. 37.
    Antonow DR. Acute pancreatitis associated with trimethoprimsulfamethoxazole. Ann Intern Med 1986; 104: 363–5PubMedGoogle Scholar
  38. 38.
    Versleijen MW, Naber AH, Riksen NP, et al. Recurrent pancreatitis after trimethoprim-sulfamethoxazole rechallenge. Neth J Med 2005; 63: 275–7PubMedGoogle Scholar
  39. 39.
    Nelis GF. Nitrofurantoin-induced pancreatitis: report of a case. Gastroenterology 1983; 84: 1032–4PubMedGoogle Scholar
  40. 40.
    Christophe JL. Pancreatitis induced by nitrofurantoin. Gut 1994; 35: 712–3PubMedCrossRefGoogle Scholar
  41. 41.
    Liviu L, Yair L, Yehuda S. Pancreatitis induced by clarithromycin. Ann Intern Med 1996; 125: 701PubMedGoogle Scholar
  42. 42.
    Schouwenberg BJ, Deinum J. Acute pancreatitis after a course of clarithromycin. Neth J Med 2003; 61: 266–7PubMedGoogle Scholar
  43. 43.
    Gonzalez Carro P, Perez Roldan F, Legaz Huidobro ML, et al. Acute pancreatitis and modified-release clarithromycin. Ann Pharmacother 2004; 38: 508–9PubMedCrossRefGoogle Scholar
  44. 44.
    Trimble GX. Acute pancreatitis induced by erythromycin. Am J Med 1989; 87: 701PubMedCrossRefGoogle Scholar
  45. 45.
    Hawksworth CR. Acute pancreatitis associated with infusion of erythromycin lactobionate [letter]. BMJ 1989; 298: 190PubMedCrossRefGoogle Scholar
  46. 46.
    Gumaste VV. Erythromycin-induced pancreatitis [letter]. Am J Med 1989; 86: 725PubMedCrossRefGoogle Scholar
  47. 47.
    Berger TM, Cook WJ, O’Marcaigh AS, et al. Acute pancreatitis in a 12-year-old girl after an erythromycin overdose. Pediatrics 1992; 90: 624–6PubMedGoogle Scholar
  48. 48.
    Fang CC, Wang HP, Lin JT. Erythromycin-induced acute pancreatitis. J Toxicol Clin Toxicol 1996; 34: 93–5PubMedCrossRefGoogle Scholar
  49. 49.
    Tenenbein MS, Tenenbein M. Acute pancreatitis due to erythromycin overdose. Pediatr Emerg Care 2005; 21: 675–6PubMedCrossRefGoogle Scholar
  50. 50.
    Chan KL, Chan HS, Lui SF, et al. Recurrent acute pancreatitis induced by isoniazid. Tuber Lung Dis 1994; 75: 383–5PubMedCrossRefGoogle Scholar
  51. 51.
    Rabassa A, Trey G, Shukla U, et al. Isoniazid-induced pancreatitis. Ann Intern Med 1994; 121: 433–4PubMedGoogle Scholar
  52. 52.
    Stephenson I, Wiselka MJ, Qualie MJ. Acute pancreatitis induced by isoniazid in the treatment of tuberculosis. Am J Gastroenterol 2001; 96: 2271–2PubMedCrossRefGoogle Scholar
  53. 53.
    Chow KM, Szeto CC, Leung CB, et al. Recurrent acute pancreatitis after isoniazid. Neth J Med 2004; 62: 172–4PubMedGoogle Scholar
  54. 54.
    Di Martino V, Ezenfis J, Benhamou Y, et al. Severe acute pancreatitis related to the use of nelfinavir in HIV infection: report of a case with positive rechallenge. AIDS 1999; 13: 1421–3PubMedCrossRefGoogle Scholar
  55. 55.
    Soylu AR, Dokmeci G, Tezel A, et al. Lamivudine-induced acute pancreatitis in a patient with decompensated Hbv-related chronic liver disease [letter]. J Clin Gastroenterol 2004; 38: 134PubMedCrossRefGoogle Scholar
  56. 56.
    Seidlin M, Lambert JS, Dolin R, et al. Pancreatitis and pancreatic dysfunction in patients taking dideoxyinosine. AIDS 1992; 6: 831–5PubMedCrossRefGoogle Scholar
  57. 57.
    Maxson CJ, Greenfield SM, Turner JL. Acute pancreatitis as a common complication of 2’,3’-dideoxyinosine therapy in the acquired immunodeficiency syndrome. Am J Gastroenterol 1992; 87: 708–13PubMedGoogle Scholar
  58. 58.
    Eland IA, Rasch MC, Sturkenboom MJ, et al. Acute pancreatitis attributed to the use of interferon alfa-2b. Gastroenterology 2000; 119: 230–3PubMedCrossRefGoogle Scholar
  59. 59.
    Tannir NM, Talpaz M, Ghazal H, et al. Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia. Leuk Lymphoma 2000; 39: 647–50PubMedCrossRefGoogle Scholar
  60. 60.
    Cecchi E, Forte P, Cini E, et al. Pancreatitis induced by pegylated interferon alfa 2b in a patient affected by chronic hepatitis C. Emerg Med Aust 2004; 16: 473–5CrossRefGoogle Scholar
  61. 61.
    Chaudhari S, Park J, Anand BS, et al. Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. Dig Dis Sci 2004; 49: 1000–6PubMedCrossRefGoogle Scholar
  62. 62.
    Tahan V, Tahan G, Dane F, et al. Acute pancreatitis attributed to the use of pegylated interferon in a patient with chronic hepatitis C. J Gastrointestin Liver Dis 2007; 16: 224–5PubMedGoogle Scholar
  63. 63.
    Ozdogan O, Tahan V, Cincin A, et al. Acute pancreatitis associated with the use of peginterferon. Pancreas 2007; 34: 485–7PubMedCrossRefGoogle Scholar
  64. 64.
    Murphey SA. Josephs AS. Acute pancreatitis associated with pentamidine therapy. Arch Intern Med 1981; 141: 56–8Google Scholar
  65. 65.
    Murphy RL, Noskin GA, Ehrenpreis ED. Acute pancreatitis associated with aerosolized pentamidine. Am J Med 1990; 88 (Suppl. 5N): 53N–6NPubMedGoogle Scholar
  66. 66.
    Gasser RA, Magill AJ, Oster CN, et al. Pancreatitis induced by pentavalent antimonials agents during treatment of Leishmaniasis. Clin Infec Dis 1993; 16: 83–90CrossRefGoogle Scholar
  67. 67.
    de Lalla F, Pellizzer G, Gradoni L, et al. Acute pancreatitis associated with the administration of meglumine antimoniate for the treatment of visceral leishmaniasis. Clin Infect Dis 1993; 16: 730–1PubMedCrossRefGoogle Scholar
  68. 68.
    Youssef SS, Iskandar SB, Scruggs J, et al. Acute pancreatitis associated with omeprazole. Int J Clin Pharmacol Ther 2005; 43: 558–61PubMedGoogle Scholar
  69. 69.
    Kawanishi H, Rudolph E, Bull FE. Azathioprine-induced acute pancreatitis [letter]. N Engl J Med 1973; 289: 357PubMedCrossRefGoogle Scholar
  70. 70.
    Paloyan D, Levin B, Simonowitz D. Azathioprine associated acute pancreatitis. Dig Dis 1977; 22: 839–46CrossRefGoogle Scholar
  71. 71.
    Guillaume P, Grandjean E, Male RJ. Azathioprine associated acute pancreatitis in the course of chronic active hepatitis. Dig Dis Sci 1984; 29: 78–80PubMedCrossRefGoogle Scholar
  72. 72.
    Cappell MS, Das KM. Rapid development of pancreatitis following reuse of 6-mercaptopurine. J Clin Gastroenterol 1989; 11: 679–81PubMedCrossRefGoogle Scholar
  73. 73.
    Sachedina B, Saibil F, Choen LB, et al. Acute pancreatitis due to 5-aminosaliscylate. Ann Intern Med 1989; 110: 490–2PubMedGoogle Scholar
  74. 74.
    Deprez P. Descamps C. Fiasse R. Pancreatitis induced by 5-aminosalicylic acid. Lancet 1989; 2(8660): 445–6PubMedCrossRefGoogle Scholar
  75. 75.
    Erdkamp F, Houben M, Ackerman E, et al. Pancreatitis induced by mesalazine. Neth J Med 1992; 41: 71–2PubMedGoogle Scholar
  76. 76.
    Toubanakis C, Batziou E, Galanopoulos G, et al. Acute pancreatitis after long term therapy with mesalazine, and hyperamylasemia associated with azathioprine in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15: 933–4PubMedCrossRefGoogle Scholar
  77. 77.
    Poldermans D, van Blankenstein M. Pancreatitis induced by disodium azodisalicylate. Am J Gastroenterol 1998; 83: 578–80Google Scholar
  78. 78.
    Suryapranata H, deVries H. Pancreatitis associated with sulfasalazine [letter]. BMJ 1986; 292: 732CrossRefGoogle Scholar
  79. 79.
    Camfield PR. Pancreatitis due to valproic acid. Lancet 1979; i: 1198–9CrossRefGoogle Scholar
  80. 80.
    Coulter DL, Allen RJ. Pancreatitis associated with valproic acid therapy for epilepsy [letter]. Ann Neurol 1980; 7: 92PubMedCrossRefGoogle Scholar
  81. 81.
    Fecik SE, Stoner SC, Raphael J, et al. Recurrent acute pancreatitis associated with valproic acid use for mood stabilization. J Clin Psychopharmacol 1999; 19: 483–4PubMedCrossRefGoogle Scholar
  82. 82.
    Koller EA, Cross JT, Doraiswamy PM, et al. Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration’s MedWatch surveillance system and published reports. Pharmacotherapy 2003; 23: 1123–30PubMedCrossRefGoogle Scholar
  83. 83.
    Bayard JM, Descamps OS, Evrard S, et al. Case report: acute pancreatitis induced by clozapine. Acta Gastroenterol Belg 2005; 68: 92–4PubMedGoogle Scholar
  84. 84.
    Wehmeier PM, Heiser P, Remschmidt H. Pancreatitis followed by pericardial effusion in an adolescent treated with clozapine. J Clin Psychopharmacol 2003; 23: 102–3PubMedCrossRefGoogle Scholar
  85. 85.
    Garlipp P, Rosenthal O, Haltenhof H, et al. The development of a clinical syndrome of asymptomatic pancreatitis and eosinophilia after treatment with clozapine in schizophrenia: implications for clinical care, recognition and management. J Clin Psychopharmacol 2002; 16: 399–400CrossRefGoogle Scholar
  86. 86.
    Cerulli TR. Clozapine-associated pancreatitis. Harv Rev Psychiatr 1999; 7: 61–3Google Scholar
  87. 87.
    Bergemann N, Ehrig C, Diebold K. Asymptomatic pancreatitis associated with clozapine. Pharmacopsychiatry 1999; 32: 78–80PubMedCrossRefGoogle Scholar
  88. 88.
    Gatto EM, Castronuovo AP, Uribe Roca MC. Clozapine and pancreatitis [letter]. Clin Neuropharmacol 1998; 21: 203PubMedGoogle Scholar
  89. 89.
    Jubert P, Fernandez R, Ruiz A. Clozapine-related pancreatitis. Ann Int Med 1994; 121: 722–3PubMedGoogle Scholar
  90. 90.
    Martin A. Acute pancreatitis associated with clozapine use [letter]. Am J Psychiatry 1992; 149: 714PubMedGoogle Scholar
  91. 91.
    Banks S, Marks IN. Hyperlipemic pancreatitis and the pill. Postgrad Med J 1970; 46: 576–88CrossRefGoogle Scholar
  92. 92.
    Davidoff F, Tishler S, Rosoff C. Marked hyperlipidemia and pancreatitis associated with oral contraceptive therapy. N Engl J Med 1973; 289: 552–5PubMedCrossRefGoogle Scholar
  93. 93.
    Parker W. Estrogen-induced pancreatitis. Clin Pharm 1983; 2: 75–9PubMedGoogle Scholar
  94. 94.
    Castro MR, Nguyen TT, O’Brien T. Clomiphene-induced severe hypertriglyceridemia and pancreatitis. Mayo Clin Proc 1999; 74: 1125–8PubMedCrossRefGoogle Scholar
  95. 95.
    Keskin M, Songur Y, Isler M. Clomiphene-induced acute pancreatitis without hypertriglyceridemia. Am J Med Sci 2007; 333: 194–6PubMedCrossRefGoogle Scholar
  96. 96.
    Blake WE, Pitcher ME. Estrogen-related pancreatitis in the setting of normal plasma lipids [case report]. Menopause 2003; 10: 99–101PubMedGoogle Scholar
  97. 97.
    Alagozlu H, Cindoruk M, Unal S. Tamoxifen-induced severe hypertriglyceridemia and acute pancreatitis. Clin Drug Investig 2006; 26: 297–302PubMedCrossRefGoogle Scholar
  98. 98.
    Lin HH, Hsu CH, Chao YC. Tamoxifen-induced severe acute pancreatitis [a case report]. Dig Dis Sci 2004; 49: 997–9PubMedCrossRefGoogle Scholar
  99. 99.
    Artac M, Sari R, Altunbas H, et al. Asymptomatic acute pancreatitis due to tamoxifen-induced severe hypertriglyceridemia in a patient with diabetes mellitus and breast cancer. J Chemother 2002; 14: 309–11PubMedGoogle Scholar
  100. 100.
    Noguchi M, Taniya T, Tajiri K, et al. Fatal hyperlipaemia in a case of metastatic breast cancer treated by tamoxifen. Br J Surg 1987; 74: 586–7PubMedCrossRefGoogle Scholar
  101. 101.
    Collis BM, George PM. Severe hypertriglyceridemia and hypercholesterolemia associated with tamoxifen use. Clin Oncol 1998; 10: 270–1CrossRefGoogle Scholar
  102. 102.
    Elisaf MS, Nakou K, Liamis G, et al. Tamoxifen-induced severe hypertriglyceridemia and pancreatitis. Ann Oncol 2000; 11: 1067–9PubMedCrossRefGoogle Scholar
  103. 103.
    Taguchi M, Yokota M, Koyano H, et al. Acute pancreatitis and parotitis induced by methimazole in a patient with Graves’ disease. Clin Endocrinol 1999; 51: 667–70CrossRefGoogle Scholar
  104. 104.
    Marazuela M, Sanchez de Paco G, Jimenez I, et al. Acute pancreatitis, hepatic cholestasis, and erythema nodosum induced by carbimazole treatment for Graves’ disease. Endocr J 2002; 49: 315–8PubMedCrossRefGoogle Scholar
  105. 105.
    Izraeli S, Adamson PC, Blaney SM, et al. Acute pancreatitis after ifosfamide therapy. Cancer 1994; 74: 1627–8PubMedCrossRefGoogle Scholar
  106. 106.
    Altman AJ, Dinndorf P, Quinn JJ. Acute pancreatitis in association with cytosine arabinoside therapy. Cancer 1982; 49: 1384–6PubMedCrossRefGoogle Scholar
  107. 107.
    McBride CE, Yavorski RT, Moses FM, et al. Acute pancreatitis associated with continuous infusion cytarabine therapy: a case report. Cancer 1996; 77: 2588–91PubMedCrossRefGoogle Scholar
  108. 108.
    McGrail LH, Sehn LH, Weiss RB, et al. Pancreatitis during therapy of acute myeloid leukemia: cytarabine related? Ann Oncol 1999; 10: 1373–6PubMedCrossRefGoogle Scholar
  109. 109.
    Shaw MT, Barnes CC, Madden FJ, et al. L-asparaginase and pancreatitis [letter]. Lancet 1970; 2: 721PubMedCrossRefGoogle Scholar
  110. 110.
    Weetman R, Baehner R. Latent onset of clinical pancreatitis in children receiving L-asparaginase therapy. Cancer 1974; 34: 780–5PubMedCrossRefGoogle Scholar
  111. 111.
    Jain R, Ramanan SV. Iatrogenic pancreatitis: a fatal complication in the induction therapy for acute lymphocytic leukemia [letter]. Arch Intern Med 1978; 138: 1726PubMedCrossRefGoogle Scholar
  112. 112.
    McLean R, Martin S, Lam-Po-Tang PR. Fatal case of L-asparaginase induced pancreatitis. Lancet 1982; 2(8312): 1401–2PubMedCrossRefGoogle Scholar
  113. 113.
    Nguyen DL, Wilson DA, Engelman ED, et al. Serial sonograms to detect pancreatitis in children receiving L-asparaginase. South Med J 1987; 80: 1133–6PubMedCrossRefGoogle Scholar
  114. 114.
    Alvarez OA, Zimmerman G. Pegasparaginase-induced pancreatitis. Med Pediatr Oncol 2000; 34: 200–5PubMedCrossRefGoogle Scholar
  115. 115.
    Top PC, Tissing WJ, Kuiper JW, et al. L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage. Pediatr Blood Cancer 2005; 44: 95–7PubMedCrossRefGoogle Scholar
  116. 116.
    Knoderer HM, Robarge J. Flockhart DA. Predicting asparaginase-associated pancreatitis. Pediatr Blood Cancer 2007; 49: 634–9CrossRefGoogle Scholar
  117. 117.
    Hastier P, Buckley MJM, Peten EP, et al. A new source of druginduced acute pancreatitis: codeine. Am J Gastroenterol 2000; 95: 3295–8PubMedCrossRefGoogle Scholar
  118. 118.
    Memon A. Pancreatitis and sulindac. Ann Intern Med 1982; 97: 139PubMedGoogle Scholar
  119. 119.
    Klein SM, Khan MA. Hepatitis, toxic epidermal necrolysis and pancreatitis in association with sulindac. J Rheumatol 1983; 10: 512–3PubMedGoogle Scholar
  120. 120.
    Zygmunt D. Acute pancreatitis with long term sulindac. West J Med 1986; 44: 461–2Google Scholar
  121. 121.
    Wargo KA, Geveden BN, McConnell VJ. Cannabinoid-induced pancreatitis: a case series. JOP 2007; 8: 579–83PubMedGoogle Scholar
  122. 122.
    Grant P, Gandhi P. A case of cannabis-induced pancreatitis. JOP 2004; 5: 41–3PubMedGoogle Scholar
  123. 123.
    Flynn WJ, Freeman PG, Wickholdt LG. Pancreatitis associated with isotretinoin induced hypertriglyceridemia [letter]. Ann Intern Med 1987; 107: 63PubMedGoogle Scholar
  124. 124.
    McCarter TL, Chen YK. Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy. Am J Gastroenterol 1992; 12: 1855–7Google Scholar
  125. 125.
    Jamshidi M, Obermeyer RJ, Govindaraj S, et al. Acute pancreatitis secondary to isotretinoin-induced hyperlipidemia. J Okla State Med Assoc 2002; 95: 79–80PubMedGoogle Scholar
  126. 126.
    Kumar AN, Schwartz DE, Lim KG. Propofol-induced pancreatitis: recurrence of pancreatitis after rechallenge. Chest 1999; 115: 1198–9PubMedCrossRefGoogle Scholar
  127. 127.
    Thomson S, Hendry W, McFarlane G, et al. Epidemiology and outcome of acute pancreatitis. Br J Surg 1987; 74: 398–401PubMedCrossRefGoogle Scholar
  128. 128.
    Lankisch PG, Droge M, Gottesleben F. Drug-induced acute pancreatitis: incidence and severity. Gut 1995; 37: 565–7PubMedCrossRefGoogle Scholar
  129. 129.
    Werth B, Kuhn M, Hartmann K, et al. Drug-induced pancreatitis: experience of the Swiss Drug Adverse Effects Centre. Schweiz Med Wochenschr 1995; 125: 731–4PubMedGoogle Scholar
  130. 130.
    Eland IA, van Puijenbroek EP, Sturkenboom MJ, et al. Drugassociated acute pancreatitis: twenty-one years of spontaneous reporting in the Netherlands. Am J Gastroenterol 1999; 94: 2417–22PubMedCrossRefGoogle Scholar
  131. 131.
    Andersen V, Sonne J, Andersen M. Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999. Eur J Clin Pharmacol 2001; 57: 517–21PubMedCrossRefGoogle Scholar
  132. 132.
    Dutta SK, Ting CD, Lai LL. Study of prevalence, severity, and etiological factors associated with acute pancreatitis in patients infected with human immunodeficiency virus. Am J Gastroenterol 1997; 92: 2044–8PubMedGoogle Scholar
  133. 133.
    Munk EM, Pedersen L, Floyd A, et al. Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study. Am J Gastroenterol 2004; 99: 884–8PubMedCrossRefGoogle Scholar
  134. 134.
    Banerjee AK, Patel KJ, Grainger SL. Drug-induced pancreatitis: a critical review. Med Toxicol Adverse Drug Exp 1989; 4: 186–98PubMedCrossRefGoogle Scholar
  135. 135.
    Tilkemeier P, Thompson P. Acute pancreatitis possibly related to enalapril. N Engl J Med 1988; 318: 275–6Google Scholar
  136. 136.
    Martin T, Taupignon A, Graf E, et al. Pancreatitis and hepatitis in a patient treated with enalapril maleate: a case report. Therapie 1989; 44: 449–50PubMedGoogle Scholar
  137. 137.
    Gonzalez Ramallo VJ, Muino Miguez A, Torres Segovia FJ. Necrotizing pancreatitis and enalapril [letter]. Eur J Med 1992; 1: 123PubMedGoogle Scholar
  138. 138.
    Jeandidier N, Klewansky M, Pinget M. Captopril-induced acute pancreatitis. Diabetes Care 1995; 18: 410–1PubMedCrossRefGoogle Scholar
  139. 139.
    Iliopoulou A, Giannakopoulous G, Pagoy H, et al. Acute pancreatitis due to captopril treatment. Dig Dis Sci 2001; 46: 1882–3PubMedCrossRefGoogle Scholar
  140. 140.
    Maliekal J, Drake CF. Acute pancreatitis associated with the use of lisinopril. Ann Pharmacother 1993; 27: 1465–6PubMedGoogle Scholar
  141. 141.
    Standridge JB. Fulminant pancreatitis associated with lisinopril therapy. South Med J 1994; 87: 179–81PubMedCrossRefGoogle Scholar
  142. 142.
    Marinella MA, Billi JE. Lisinopril therapy associated with acute pancreatitis. West J Med 1995; 163: 77–8PubMedGoogle Scholar
  143. 143.
    Kanbay M, Sekuk H, Yilmaz U, et al. Acute pancreatitis associated with combined lisinopril and atorvastatin therapy. Dig Dis 2005; 23: 92–4PubMedCrossRefGoogle Scholar
  144. 144.
    Arjomand H, Kemp DG. Quinapril and pancreatitis. Am J Gastroenterol 1999; 94: 290–1PubMedGoogle Scholar
  145. 145.
    Anagnostopoulos GK, Kostopoulos P, Tsiakos S, et al. Fulminant pancreatitis associated with ramipril therapy. Pancreas 2003; 27: 278–9PubMedCrossRefGoogle Scholar
  146. 146.
    Gallego-Rojo FJ, Gonzalez-Calvin JL, Guilarte J, et al. Perindopril-induced acute pancreatitis. Dig Dis Sci 1997; 42: 1789–91PubMedCrossRefGoogle Scholar
  147. 147.
    Eland IA, Sundstrom A, Velo GP, et al. Antihypertensive medication and the risk of acute pancreatitis: the European casecontrol study on drug-induced acute pancreatitis. Scand J Gastroenterol 2006; 41: 1484–90PubMedCrossRefGoogle Scholar
  148. 148.
    Baffoni L, Durante V, Grossi M. Acute pancreatitis induced by telmisartan overdose [letter]. Ann Pharmacother 2004; 38: 1088PubMedCrossRefGoogle Scholar
  149. 149.
    Cjaka C, Buclin T, Brunner HR, et al. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonist. Clin Pharmacokinet 1997; 1: 1–29Google Scholar
  150. 150.
    Leung PS. Local rennin-angiotensin system in the pancreas. JOP J Pancreas (Online) 2001; 2: 3–8 [online]. Available from URL: http://www.joplink.net [Accessed 2008 Aug 25]Google Scholar
  151. 151.
    McDonald KB, Garber BG, Perreault MM. Pancreatitis associated with simvastatin plus fenofibrate. Ann Pharmacother 2002; 36: 275–9PubMedCrossRefGoogle Scholar
  152. 152.
    Antonopoulos S, Mikros S, Kokkoris S, et al. A case of acute pancreatitis possibly associated with combined salicylate and simvastatin treatment. JOP 2005; 6: 264–8PubMedGoogle Scholar
  153. 153.
    Miltiadous G, Anthopoulou A, Elisaf M. Acute pancreatitis possibly associated with combined salicylate and atorvastatin. therapy. JOP 2003; 4: 20–1Google Scholar
  154. 154.
    Kanbay M, Sekuk H, Yilmaz U, et al. Acute pancreatitis associated with combined lisinopril and atorvastatin therapy. Dig Dis 2005; 23: 92–4PubMedCrossRefGoogle Scholar
  155. 155.
    Singh S, Nautiyal A, Dolan JG. Recurrent acute pancreatitis possibly induced by atorvastatin and rosuvastatin: is statin induced pancreatitis a class effect? JOP 2004; 5: 502–4PubMedGoogle Scholar
  156. 156.
    Wong PW, Dillard TA, Kroenke K. Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy. South Med J 1998; 91: 202–5PubMedCrossRefGoogle Scholar
  157. 157.
    Abdul-Ghaffar NU, el-Sonbaty MR. Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozil therapy. J Clin Gastroenterol 1995; 21: 340–1PubMedCrossRefGoogle Scholar
  158. 158.
    Tsigrelis C, Pitchumoni CS. Pravastatin: a potential cause for acute pancreatitis. World J Gastroenterol 2006; 12: 7055–7PubMedGoogle Scholar
  159. 159.
    Singh S, Loke YK. Statins and pancreatitis: a systematic review of observational studies and spontaneous case reports. Drug Saf 2006; 29: 1123–32PubMedCrossRefGoogle Scholar
  160. 160.
    Thisted H, Jacobsen J, Munk EM, et al. Statins and the risk of acute pancreatitis: a population-based case-control study. Aliment Pharmacol Ther 2006; 23: 185–90PubMedCrossRefGoogle Scholar
  161. 161.
    Ober WB, LeCompte PM. Acute fatty metamorphosis of the liver associated with pregnancy. Am J Med 1955; 19: 743–58PubMedCrossRefGoogle Scholar
  162. 162.
    Schultz J, Adamson J, Workman W, et al. Fatal liver disease after intravenous administration of tetracycline in high dosage. N Engl J Med 1963; 269: 999–1004PubMedCrossRefGoogle Scholar
  163. 163.
    Whalley PJ, Adams RH, Combes B. Tetracycline toxicity in pregnancy: liver and pancreatic dysfunction. JAMA 1964; 189: 103–8CrossRefGoogle Scholar
  164. 164.
    Kunelis CT, Peters JL, Edmondson HA. Fatty liver of pregnancy and its relationship to tetracycline therapy. Am J Med 1965; 38: 359–77PubMedCrossRefGoogle Scholar
  165. 165.
    Peters R, Edmondson H, Mikkelsen WP, et al. Tetracycline induced fatty liver in non-pregnant patients: a report of six cases. Am J Surg 1967; 113: 622–32PubMedCrossRefGoogle Scholar
  166. 166.
    Nicolau DP, Mengedoht DE, Kline JJ. Tetracycline induced pancreatitis. Am J Gastroenterol 1991; 86: 1669–71PubMedGoogle Scholar
  167. 167.
    Steinberg WM. Acute drug and toxin induced pancreatitis. Hosp Pract 1985; 20: 95–102Google Scholar
  168. 168.
    Plotnick BH, Cohen I, Tsang T, et al. Metronidazole-induced pancreatitis. Ann Intern Med 1985; 103: 891–2PubMedGoogle Scholar
  169. 169.
    Corey WA, Doebbeling BN, DeJong KJ, et al. Metronidazoleinduced acute pancreatitis. Rev Infect Dis 1991; 13: 1213–5PubMedCrossRefGoogle Scholar
  170. 170.
    Sura ME, Heinrich KA, Suseno M. Metronidazole-associated pancreatitis. Ann Pharmacother 2000; 34: 1152–5PubMedCrossRefGoogle Scholar
  171. 171.
    Feola DJ, Thornton AC. Metronidazole-induced pancreatitis in a patient with recurrent vaginal trichomoniasis. Pharmacotherapy 2002; 22: 1508–10PubMedCrossRefGoogle Scholar
  172. 172.
    Nigwekar SU, Casey KJ. Metronidazole induced pancreatitis: a case report and review of the literature. JOP 2004; 5: 516–9PubMedGoogle Scholar
  173. 173.
    Tsesmeli NE. Giannoulis KE. Savopoulos CG, et al. Acute pancreatitis as a possible consequence of metronidazole during a relapse of ulcerative colitis. Eur J Gastroenterol Hepatol 2007; 19: 805–6PubMedCrossRefGoogle Scholar
  174. 174.
    Friedman GD, Selby JV. How often does metronidazole induce pancreatitis? Gastroenterology 1990; 98: 1702–3PubMedGoogle Scholar
  175. 175.
    Wallace JR, Cushing RD, Bawdon RE, et al. Assessment of antimicrobial penetrance into the pancreatic juice in humans. Surg Gynecol Obstet 1986; 162: 313–6PubMedGoogle Scholar
  176. 176.
    Kvale PA, Parks RD. Acute abdomen: an usual reaction to isoniazid. Chest 1975; 68: 271–2PubMedCrossRefGoogle Scholar
  177. 177.
    Mendoza JL, Lana R, Espinos D, et al. Acute pancreatitis induced by isoniazid, a causal association. Ann Med Interne (Paris) 1998; 15: 588–90Google Scholar
  178. 178.
    Izzedine H, Launay-Vachar V, Stomme T, et al. Acute pancreatitis induced by isoniazid. Am J Gastroenterol 2001; 96: 3208–9PubMedCrossRefGoogle Scholar
  179. 179.
    Jin CF, Sabie R. Isoniazid-induced acute hepatitis and acute pancreatitis in a patient during chemoprophylaxis. J Clin Gastroenterol 2002; 35: 100–1PubMedCrossRefGoogle Scholar
  180. 180.
    Chan TY. Isoniazid and rifampicin rarely cause acute pancreatitis in patients with tuberculosis [letter]. Int J Clin Pharmacol Ther 1999; 37: 109PubMedGoogle Scholar
  181. 181.
    Mattson K. Side effects of rifampicin: a clinical study. Scand J Respir Dis 1973; 82 Suppl.: 8–52Google Scholar
  182. 182.
    Broeckaert van Orshoven A, Michielsen P, Vandepitte J. Fatal leishmaniasis in a renal transplant recipient. Lancet 1979; ii: 740–1CrossRefGoogle Scholar
  183. 183.
    McCarthy A, Keystone J, Kain K. Pancreatitis occurring during therapy with stibogluconate: two case reports. Clin Infect Dis 1993; 17: 952–3PubMedCrossRefGoogle Scholar
  184. 184.
    Laguna F, Soriano V, Gonzalez-Labor J. Misdiagnosis in patients receiving treatment with pentavalent antimonial patients. Clin Infect Dis 1994; 19: 978–9PubMedGoogle Scholar
  185. 185.
    Aronson NE, Wortmann GW, Johnson SC, et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent US military experience. Clin Infect Dis 1998; 27: 1457–64PubMedCrossRefGoogle Scholar
  186. 186.
    Wortmann G, Miller SR, Oster C. a randomized, double-blind study of the efficacy of a 10-or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis 2002; 35: 261–7PubMedCrossRefGoogle Scholar
  187. 187.
    McBride MO, Linney M, Davidson RN, et al. Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate [letter]. Clin Infect Dis 1995; 21: 710PubMedCrossRefGoogle Scholar
  188. 188.
    Delgado J, Macias J, Pineda JA, et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodificiency virus type-1 infected patients. Am J Trop Med Hyg 1999; 61: 766–9PubMedGoogle Scholar
  189. 189.
    Brundtland GH. World Health Organization Report on Infectious Diseases 2000. Overcoming antimicrobial resistance [on-line]. Available from URL: http://www.who.int/infectious-dis-ease-report/2000/[Accessed 2008 Aug 25]
  190. 190.
    Johnson WC, Nasbeth DC. Pancreatitis in renal transplantation. Ann Surg 1970; 171: 309–14PubMedCrossRefGoogle Scholar
  191. 191.
    Nogueira JR, Freedman MA. Acute pancreatitis as a complication of imuran therapy in regional enteritis. Gastroenterology 1972; 62: 1040–1PubMedGoogle Scholar
  192. 192.
    Sturdevant RAL, Singleton JW, Deren JJ, et al. Azathioprinerelated pancreatitis in patients with Crohn’s disease. Gastroenterology 1979; 77: 883–6PubMedGoogle Scholar
  193. 193.
    Bank L, Wright JP. 6-Mercaptopurine-related pancreatitis in 2 patients with inflammatory bowel disease. Dig Dis Sci 1984; 29: 357–9PubMedCrossRefGoogle Scholar
  194. 194.
    Haber CJ, Meltzer SJ, Present DH, et al. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 1986; 91: 982–6PubMedGoogle Scholar
  195. 195.
    Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short and long-term toxicity. Ann Intern Med 1989; 111: 641–9PubMedGoogle Scholar
  196. 196.
    Floyd A, Pedersen L, Nielsen GL, et al. Risk of acute pancreatitis in users of azathioprine: a population-based case-control study. Am J Gastroenterol 2003; 98: 1305–8PubMedGoogle Scholar
  197. 197.
    Block MB, Genant HK, Kirsner JB. Pancreatitis as an adverse reaction to salicylazosulfapuridine. N Engl J Med 1970; 282: 380–2PubMedCrossRefGoogle Scholar
  198. 198.
    Faintuch J, Mott C, Machado M. Pancreatitis and pancreatic necrosis during sulfasalazine therapy. Int Surg 1985; 70: 271–2PubMedGoogle Scholar
  199. 199.
    Rubin R. Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis. Am J Gastroenterol 1994; 89: 789–91PubMedGoogle Scholar
  200. 200.
    Garau P, Orenstein S, Neigut D, et al. Pancreatitis associated with olsalazine and sulfasalazine in children with ulcerative colitis. J Pediatr Gastroenterol Nutr 1994; 18: 481–5PubMedCrossRefGoogle Scholar
  201. 201.
    Isaacs KL, Murphy D. Pancreatitis after rectal administration of 5-aminosalicylic acid. J Clin Gastroenterol 1990; 12: 198–9PubMedCrossRefGoogle Scholar
  202. 202.
    Fernandez J, Sala M, Panes J, et al. Acute pancreatitis after long term 5-aminosalicylic acid therapy. Am J Gastroenterol 1997; 92: 2302–3PubMedGoogle Scholar
  203. 203.
    Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002; 51: 536–9PubMedCrossRefGoogle Scholar
  204. 204.
    Fiorentini MT, Fracchia M, Galatola G, et al. Acute pancreatitis during oral 5-aminosalicylic acid therapy. Dig Dis Sci 1990; 35(9): 1180–2PubMedCrossRefGoogle Scholar
  205. 205.
    Debongnie J, Dekoninck X. Sulfasalazine, 5-ASA, and acute pancreatitis in Crohn’s disease. J Clin Gastroenterol 1994; 19: 348–9PubMedCrossRefGoogle Scholar
  206. 206.
    Butalden PB, Van Dyne BJ, Cloyd J. Pancreatitis associated with valproic acid therapy. Pediatrics 1979; 64: 520–2Google Scholar
  207. 207.
    Buzan RD, Firestone D, Thomas M, et al. Valproate-associated pancreatitis and cholecystitis in six mentally retarded adults. J Clin Psychiatry 1995; 56: 529–32PubMedGoogle Scholar
  208. 208.
    Parker PH, Helinek GL, Ghishan FK, et al. Recurrent pancreatitis induced by valproic acid. Gastroenterology 1981; 80: 826–8PubMedGoogle Scholar
  209. 209.
    Williams LH, Reynolds RP, Emery JL. Pancreatitis during sodium valproate treatment. Arch Dis Child 1983; 58: 543–4PubMedCrossRefGoogle Scholar
  210. 210.
    Wyllie E, Wyllie R, Cruse RP, et al. Pancreatitis associated with valproic acid therapy. Am J Dis Child 1984; 138: 912–4PubMedGoogle Scholar
  211. 211.
    Baskies AM. Pancreatic pseudocyst associated with valproic acid therapy. J Med Soc N J 1984; 81: 399–400PubMedGoogle Scholar
  212. 212.
    Ford DM, Portman RJ, Lum GM. Pancreatitis in children on chronic dialysis treated with valproic acid. Pediatr Nephrol 1990; 4: 259–61PubMedCrossRefGoogle Scholar
  213. 213.
    Evans RJ, Miranda RN, Jordan J. Fatal acute pancreatitis caused by valproic acid. Am J Forensic Med Pathol 1995; 16: 62–5PubMedCrossRefGoogle Scholar
  214. 214.
    Lott JA, Bond LW, Bobo RC, et al. Valproic acid-associated pancreatitis: report of three cases and a brief review. Clin Chem 1990; 36: 395–7PubMedGoogle Scholar
  215. 215.
    Sinclair DB, Berg M, Breault R. Valproic acid-induced pancreatitis in childhood epilepsy: case series and review. J Child Neurol 2004; 19: 498–02PubMedCrossRefGoogle Scholar
  216. 216.
    Werlin SL, Kugathasa S, Frautschy BC. Pancreatitis in children. J Pediatr Gastroenterol Nutr 2003; 37: 591–5PubMedCrossRefGoogle Scholar
  217. 217.
    Zorilla E, Hulse M, Hernandez A, et al. Severe endogenous hypertriglyceridemia during treatment with estrogen and oral contraceptives. J Clin Endocrinol Metab 1968; 28: 1793–6CrossRefGoogle Scholar
  218. 218.
    Glueck CJ, Scheel D, Fishback J, et al. Estrogen-induced pancreatitis in patients with previously covert familial type 5 hyperlipoproteinemia. Metabolism 1972; 21: 657–66PubMedCrossRefGoogle Scholar
  219. 219.
    Anon. Pancreatitis from oral contraceptives [editorial]. BMJ 1973; 4: 688–9CrossRefGoogle Scholar
  220. 220.
    Molitich ME, Oill P, Odell WD. Massive hyperlipemia during estrogen therapy. JAMA 1974; 227: 522–5CrossRefGoogle Scholar
  221. 221.
    Foster ME, Powell DEB. Pancreatitis, multiple infarcts, and oral contraception. Postgrad Med J 1975; 51: 667–9PubMedCrossRefGoogle Scholar
  222. 222.
    Mungall IP, Hague RV. Pancreatitis and the pill. Postgrad Med J 1975; 51: 855–7PubMedCrossRefGoogle Scholar
  223. 223.
    Glueck CJ, Scheel D, Fishback J, et al. Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. J Lab Clin Med 1994; 123: 59–64PubMedGoogle Scholar
  224. 224.
    Ruman J, Brenner S, Sauer MV. Severe hypertriglyceridemia and pancreatitis following hormone replacement prior to cryothaw transfer. J Assist Reprod Genet 2002; 19: 94–7PubMedCrossRefGoogle Scholar
  225. 225.
    Perego E, Scaini A, Romano F, et al. Estrogen-induced severe acute pancreatitis in a male. JOP J Pancreas (Online) 2004; 5(5): 353–6 [online]. Available from URL: http://www.joplink.net [Accessed 2008 Aug 25]Google Scholar
  226. 226.
    Stuyt PM, Demacker PN, Stalenhoef AF. Pancreatitis induced by oestrogen in a patient with type I hyperlipoproteinemia [letter]. BMJ (Clin Res Ed) 1986; 293: 734CrossRefGoogle Scholar
  227. 227.
    Wallace RB, Hoover J, Sandler D, et al. Altered plasma lipids associated with oral contraceptive or estrogen consumption. Lancet 1977; 2: 11–4PubMedCrossRefGoogle Scholar
  228. 228.
    Stokes T, Wynn V. Serum lipids in women on oral contraceptives. Lancet 1971; 2: 677–80PubMedCrossRefGoogle Scholar
  229. 229.
    Lankisch PG, Niederstadt H, Redlin-Kress E, et al. Acute pan-creatitis: induced by heroin intoxication? Pancreas 1993; 8: 123–6PubMedCrossRefGoogle Scholar
  230. 230.
    Beamish N, Schwarer P, Watson AM. Acute pancreatitis complicating a bone marrow harvest. Bone Marrow Transplant 1997; 19: 525–6PubMedCrossRefGoogle Scholar
  231. 231.
    Moreno Escobosa MC, Amat Lopez J, Cruz Granados S, et al. Pancreatitis due to codeine. Allergol Immunopathol 2005; 33: 175–7CrossRefGoogle Scholar
  232. 232.
    Steinberg WM, Toskes PP, Salvato RF. Non-specificity of the morphine-prostigmine test [abstract]. Gastroenterology 1979; 76: A1255Google Scholar
  233. 233.
    Roberts-Thompson IC, Toouli J. Abnormal responses to morphine-neostigmine in patients with undefined biliary-type pain. Gut 1985; 26: 1367–72CrossRefGoogle Scholar
  234. 234.
    Gross JB, Comfort MW, Mathieson DR, et al. Elevated values for serum enzymes and lipase following the administration of opiates: a preliminary report. Proc Mayo Clinic 1951; 26: 81–7Google Scholar
  235. 235.
    Goldstein J, Laskin DA, Ginsberg GH. Sulindac associated pancreatitis. Ann Intern Med 1980; 93: 151PubMedGoogle Scholar
  236. 236.
    Siefkin AD. Sulindac and pancreatitis. Ann Intern Med 1980; 93: 932–3PubMedGoogle Scholar
  237. 237.
    Lilly EL. Pancreatitis after administration of sulindac [letter]. JAMA 1981; 246: 2680PubMedCrossRefGoogle Scholar
  238. 238.
    Lerche A. Vyberg, M. Kirkegaard, E. Acute cholangitis and pancreatitis associated with sulindac (clinoril). Histopathology 1987; 11: 647–53Google Scholar
  239. 239.
    Sugarman HJ. Sulindac-induced acute pancreatitis mimicking gallstone pancreatitis. Am Surg 1989; 55: 536–8Google Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Division of Gastromorphine-enterology, Hepatology, and NutritionWinthrop University HospitalMineolaUSA
  2. 2.School of MedicineState University of New YorkNew YorkUSA

Personalised recommendations